News stories about Chemours (NYSE:CC) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemours earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the specialty chemicals company an impact score of 45.0197606482358 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
CC has been the topic of a number of recent analyst reports. Zacks Investment Research raised Chemours from a “hold” rating to a “buy” rating and set a $57.00 target price on the stock in a research report on Thursday, November 9th. Jefferies Group boosted their target price on Chemours to $66.00 and gave the stock a “buy” rating in a research report on Monday, December 4th. Goldman Sachs Group lowered Chemours from a “buy” rating to a “neutral” rating and set a $55.00 target price on the stock. in a research report on Wednesday, December 6th. Barclays reaffirmed a “buy” rating and set a $60.00 target price on shares of Chemours in a research report on Wednesday, December 6th. Finally, UBS Group boosted their target price on Chemours from $50.00 to $59.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $57.89.
Shares of Chemours (NYSE:CC) traded down $0.52 during mid-day trading on Friday, hitting $52.47. The stock had a trading volume of 872,489 shares, compared to its average volume of 2,470,000. Chemours has a twelve month low of $23.39 and a twelve month high of $58.08. The company has a quick ratio of 1.63, a current ratio of 2.19 and a debt-to-equity ratio of 5.07. The stock has a market capitalization of $9,700.00 and a P/E ratio of 36.19.
Chemours (NYSE:CC) last issued its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.11. Chemours had a return on equity of 116.80% and a net margin of 4.86%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the previous year, the company posted $0.61 earnings per share. Chemours’s revenue for the quarter was up 13.3% compared to the same quarter last year. analysts anticipate that Chemours will post 3.65 EPS for the current fiscal year.
Chemours declared that its Board of Directors has approved a share repurchase plan on Friday, December 1st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the specialty chemicals company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.17 per share. This is an increase from Chemours’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.30%. Chemours’s payout ratio is currently 8.28%.
In other Chemours news, insider E Bryan Snell sold 11,878 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $53.25, for a total value of $632,503.50. Following the transaction, the insider now owns 63,063 shares in the company, valued at $3,358,104.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christian W. Siemer sold 15,088 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $47.37, for a total value of $714,718.56. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.